Biomarcadores para fibrosis hepática, avances, ventajas y desventajas

Rojkind, 1994, The extracellular matrix and the liver, 843 Bedossa, 2003, Liver extracellular matrix in health and disease, J Pathol, 200, 504, 10.1002/path.1397 Friedman, 2000, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, J Biol Chem, 275, 2247, 10.1074/jbc.275.4.2247 Sistema Nacional de Información en Salud (SINAIS). Informe de funciones generales de la Secretaría de Salud, 2008 [consultado 14 Feb 2013]. Disponible en: http://www.sinais.salud.gob.mx/mortalidad/index.html Sebastiani, 2006, Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy, World J Gastroenterol, 12, 3682, 10.3748/wjg.v12.i23.3682 Bedossa, 1996, An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatol, 24, 289, 10.1002/hep.510240201 Regev, 2002, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection, Am J Gastroenterol, 97, 2614, 10.1111/j.1572-0241.2002.06038.x Colloredo, 2003, Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease, J Hepatol, 39, 239, 10.1016/S0168-8278(03)00191-0 Siddique, 2003, Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection, Scand J Gastroenterol, 38, 427, 10.1080/00365520310000825 Janiec, 2005, Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies, Obes Surg, 15, 497, 10.1381/0960892053723268 Bedossa, 2003, Sampling variability of liver fibrosis in chronic hepatitis C, Hepatol, 38, 1449, 10.1016/j.hep.2003.09.022 Piccinino, 1986, Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies, J Hepatol, 2, 165, 10.1016/S0168-8278(86)80075-7 Rockey, 2009, Liver biopsy, Hepatol, 49, 1017, 10.1002/hep.22742 Terjung, 2003, Bleeding complications after percutaneous liver biopsy. An analysis of risk factors, Digestion, 67, 138, 10.1159/000071293 West, 2010, Reduced mortality rates following elective percutaneous liver biopsies, Gastroenterology, 139, 1230, 10.1053/j.gastro.2010.06.015 Gressner, 2007, Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver dependent malfunction tests, Clin Chim Acta, 381, 107, 10.1016/j.cca.2007.02.038 Iredale, 2007, Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ, J Clin Invest, 117, 539, 10.1172/JCI30542 Plebani, 1991, Biochemical markers of hepatic fibrosis, Clin Biochem, 24, 219, 10.1016/0009-9120(91)80013-S Castera, 2012, Noninvasive methods to assess liver disease in patients with hepatitis B or C, Gastroenterology, 142, 1293, 10.1053/j.gastro.2012.02.017 Zhou, 2009, Assessment of fibrosis in chronic liver diseases, J Dig Dis, 10, 7, 10.1111/j.1751-2980.2008.00356.x Baranova, 2011, Non-invasive markers for hepatic fibrosis, BMC Gastroenterol, 11, 91, 10.1186/1471-230X-11-91 Gressner, 2009, Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey, World J Gastroenterol, 15, 2433, 10.3748/wjg.15.2433 Grigorescu, 2006, Noninvasive biochemical markers of liver fibrosis, J Gastrointestin Liver Dis, 15, 149 Haukeland, 2008, AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis, Scand J Gastroenterology, 43, 1241, 10.1080/00365520802158614 Giboney, 2005, Mildly elevated liver transaminase levels in the asymptomatic patient, Am Fam Physician, 71, 1105 Green, 2002, AGA technical review on the evaluation of liver chemistry tests, Gastroenterology, 123, 1367, 10.1053/gast.2002.36061 Giannini, 2003, Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease, Arch Intern Med, 163, 218, 10.1001/archinte.163.2.218 Croquet, 2002, Prothrombin index is an indirect marker of severe liver fibrosis, Eur J Gastroenterol Hepatol, 14, 1133, 10.1097/00042737-200210000-00015 Pilette, 1999, Non-invasive diagnosis of esophageal varices in chronic liver diseases, J Hepatol, 31, 867, 10.1016/S0168-8278(99)80288-8 Jarcuska, 2010, Circulating markers of liver fibrosis progression, Clin Chim Acta, 411, 1009, 10.1016/j.cca.2010.04.009 Murawaki, 2001, Diagnostic value of serum type iv collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis, J Gastroenterol Hepatol, 16, 777, 10.1046/j.1440-1746.2001.02515.x Kanzler, 2001, Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor beta, J Viral Hepat, 8, 430, 10.1046/j.1365-2893.2001.00314.x Lydatakis, 2006, Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease, Liver Int, 26, 864, 10.1111/j.1478-3231.2006.01312.x Greenlee, 2007, Matrix metalloproteinases in lung: Multiple, multifarious, and multifaceted, Physiol Rev, 87, 69, 10.1152/physrev.00022.2006 Mölleken, 2009, Detection of novel biomarkers of liver cirrhosis by proteomic analysis, Hepatol, 49, 1257, 10.1002/hep.22764 Adams, 2011, Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease, J Gastroenterol Hepatol, 26, 1536, 10.1111/j.1440-1746.2011.06774.x Imbert-Bismut, 2001, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study, Lancet, 357, 1069, 10.1016/S0140-6736(00)04258-6 Lu, 2003, Relationship between clinical and pathologic findings in patients with chronic liver diseases, World J Gastroenterol, 9, 2796, 10.3748/wjg.v9.i12.2796 Nguyen-Khac, 2008, Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests, Aliment Pharmacol Ther, 28, 1188, 10.1111/j.1365-2036.2008.03831.x Ahmad, 2011, A brief review on molecular, genetic and imagingtechniques for HCV fibrosis evaluation, Virol J, 8, 53, 10.1186/1743-422X-8-53 Dalla Piazza, 2010, Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients, BMC Infect Dis, 10, 116, 10.1186/1471-2334-10-116 Lin, 2011, Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis, Hepatology, 53, 726, 10.1002/hep.24105 Wenwen, 2012, Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: A leading meta-analysis, BMC Gastroenterol, 12, 14, 10.1186/1471-230X-12-14 Forns, 2002, Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model, Hepatology., 36, 986, 10.1053/jhep.2002.36128 Guechot, 2010, Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort, Clin Chim Acta, 411, 86, 10.1016/j.cca.2009.10.011 Adams, 2005, Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection, Clin Chem, 51, 1867, 10.1373/clinchem.2005.048389 Imbert-Bismut, 2004, Intra-laboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (Actitest) and reference ranges in healthy blood donors, Clin Chem Lab Med, 42, 323, 10.1515/cclm.2004.42.6.681 Poynard, 2012, Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population, J Hepatol, 57, 541, 10.1016/j.jhep.2012.04.025 Kim, 2012, Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B, PLoS One, 7, e35825, 10.1371/journal.pone.0035825 Munteanu, 2008, Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience, J Gastrointestin Liver Dis, 17, 187 Fouad, 2013, Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study, Int J Gen Med, 6, 127 Palmeri, 2011, Acoustic radiation force-based elasticity imaging methods, Interface Focus, 1, 553, 10.1098/rsfs.2011.0023 Vergniol, 2011, Noninvansive tests for fibrosis and liver stiffness predict 5 years outcomes of patients with chronic hepatitis C, Gastroenterology, 140, 1970, 10.1053/j.gastro.2011.02.058 Nightingale, 2011, Acoustic radiation force impulse (ARFI) imaging: A review, Curr Med Imaging Rev, 7, 328, 10.2174/157340511798038657 Kim, 2010, What are «true normal» liver stiffness values using FibroScan? A prospective study in healthy living liver and kidney donors in South Korea, Liver Int, 30, 268, 10.1111/j.1478-3231.2009.02172.x Degos, 2010, Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study), J Hepatol, 53, 1013, 10.1016/j.jhep.2010.05.035 Friedrich-Rust, 2008, Performance of transient elastography for the staging of liver fibrosis: a metaanalysis, Gastroenterology, 134, 960, 10.1053/j.gastro.2008.01.034 Wong, 2013, Trasiente elastography: Kill two birds with one stone?, World Hepatol, 5, 264, 10.4254/wjh.v5.i5.264 Clouston, 2007, Steatosis as a cofactor in other liver diseases: Hepatitis C virus, alcohol, hemochromatosis, and others, Clin Liver Dis, 11, 173, 10.1016/j.cld.2007.02.007 Sasso, 2010, Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 Engelmann, 2012, Feasibility study and control values of transient elastography in healthy children, Eur J Pediatr, 171, 353, 10.1007/s00431-011-1558-7 De Lédinghen, 2010, Feasibility of liver transient elastography with FibroScan using a new probe for obese patients, Liver Int, 30, 1043, 10.1111/j.1478-3231.2010.02258.x De Lédinghen, 2012, Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®, J Hepatol, 56, 833, 10.1016/j.jhep.2011.10.017 Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038/ajg.2012.331 Forestier, 2012, Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C, J Gastrointestin Liver Dis, 21, 367 Talwalkar, 2008, Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications, Hepatology, 47, 332, 10.1002/hep.21972 Naganawa, 2005, Diffusion-weighted imaging of the liver: Technical challenges and prospects for the future, Magn Reson Med Sci, 4, 175, 10.2463/mrms.4.175 Yin, 2007, Assessment of hepatic fibrosis with magnetic resonance elastography, Clin Gastro Hep, 5, 1207, 10.1016/j.cgh.2007.06.012 Klatt, 2006, In vivo determination of hepatic stiffness using steady-state free precision magnetic resonance elastography, Invest Radiol, 41, 841, 10.1097/01.rli.0000244341.16372.08 Huwart, 2008, Magnetic resonance elastography for the noninvasive staging of liver fibrosis, Gastroenterology, 135, 32, 10.1053/j.gastro.2008.03.076 Fontana, 2010, Serum fibrosis markers are associated with liver disease progression in nonresponder patients with chronic hepatitis C, Gut, 59, 1401, 10.1136/gut.2010.207423 Poynard, 2004, Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C, Clin Chem, 10, 1 Park, 2011, Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B, J Clin Gastroenterol, 45, 361, 10.1097/MCG.0b013e31820d3458 Willis, 2008, Spectrum bias—why clinicians need to be cautious when applying diagnostic test studies, Family Practice., 25, 390, 10.1093/fampra/cmn051 Goehring, 2004, Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance, Statist. Med., 23, 125, 10.1002/sim.1591 Myers, 2010, Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy, Liver Int., 30, 1471, 10.1111/j.1478-3231.2010.02331.x Fraquelli, 2011, Etiology-related determinants of liver stiffness values in chronic viral hepatitis Bor C J Hepatol., 54, 621 Wells, 2011, Medical ultrasound: imaging of soft tissue strain and elasticity, J R Soc Interface., 8, 1521, 10.1098/rsif.2011.0054 Callewaert, 2004, Non invasive diagnosis of liver cirrhosis using DNA sequence-based total serum protein glycomics, Nat Med., 10, 429, 10.1038/nm1006 Blomme, 2009, Alteration of protein glycosylation in liver diseases, J Hepatol., 50, 592, 10.1016/j.jhep.2008.12.010 Kuno, 2013, A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis, Sci Rep., 3, 1065, 10.1038/srep01065 Younossi, 2010, Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis, J Proteome Res., 9, 3218, 10.1021/pr100069e Chou, 2013, Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review, Ann Intern Med., 158, 807, 10.7326/0003-4819-158-11-201306040-00005